The biggest short-term problem for pharmaceutical stocks is not the fundamentals, but the chip structure. To go well is estimated to need 2 weeks to 4 weeks of time, the inflection point will appear. Organized the relevant stocks for your reference.
1, Hengrui medicine (chemical pharmaceutical)
Current price: 40.95, total market capitalization: 261.9 billion, circulating market capitalization: 261.2 billion, 2021 three quarters: 0.66
Theme concepts: Domestic chemical pharmaceuticals, innovative drug leader. A shares of the largest market value of the pharmaceutical stocks.
Main business: pharmaceutical research and development, production and sales.
2, Huahai Pharmaceuticals (chemical pharmaceuticals)
Current price: 20.99, total market capitalization: 31.3 billion, market capitalization in circulation: 30.5 billion, three quarters of 2021: 0.41
Theme Concept: a leading company in the domestic specialty API industry, and is the world's largest provider of Prilosec and Sartan drugs.
Main business: manufacturing and sales of tablets, hard capsules, APIs and pharmaceutical intermediates.
3, Tonghua Dongbao (chemical pharmaceuticals)
Current price: 10.15, total market capitalization: 20.6 billion, circulating market capitalization: 20.6 billion, three quarters of 2021: 0.52
Theme concept: the leading domestic insulin stocks.
Main business: production and sales of Chinese and Western patent medicines, biological products and plastic building materials.
4, WuXi AppTec (pharmaceutical R & D)
Current price: 104.80, total market capitalization: 309.8 billion, circulating market capitalization: 266.9 billion, three quarters of 2021: 1.22
Theme concept: CXO complete industrial chain leader, small molecule drug preclinical CRO, domestic chemical pharmaceuticals. CMO ranked first.
Main business: the main business for the discovery of small molecule chemical drugs, R & D and production of a full range of integrated platform services, in the form of the whole industry chain platform for the global pharmaceutical companies to provide all kinds of new drug R & D, production and ancillary services; In addition, the issuer is also outside the country to provide medical device testing and offshore precision medical R & D and production services.
5, Zhaoyan new drugs (pharmaceutical research and development)
Current price: 96.88, total market capitalization: 36.9 billion, the circulation of the market capitalization: 31 billion, three quarters of 2021: 0.95
Theme concepts: non-clinical safety of the drug leader, drug preclinical research services.
Main business: drug preclinical research services and sales of laboratory animals and ancillary products, with drug non-clinical safety evaluation services as the main focus.
6, Myriad Medical (medical devices)
Current price: 323.28, total market capitalization: 393 billion, the circulating market capitalization: 393 billion, three quarters of 2021: 5.48
Theme Concept: Domestic medical equipment leader.
Main business: engaged in the research and development of medical equipment, manufacturing, marketing and service, always customer demand-oriented, committed to providing quality products and services for the global medical institutions.
7, Kellettai (medical devices)
Current price: 9.10, total market capitalization: 6.553 billion, circulating market capitalization: 6.521 billion, three quarters of 2021: 0.28
Theme Concepts: Vertebroplasty Minimally Invasive Interventional Surgery System, orthopedic surgical instrument leader.
Main business: research and development, production and sales of vertebroplasty minimally invasive interventional surgery system.
8, Shouxiangu (proprietary Chinese medicine)
Current price: 52.46, total market capitalization: 8 billion, circulating market capitalization: 8 billion, 2021 three quarters: 0.58
Theme concepts: domestic ganoderma leading.
Main business: engaged in ganoderma lucidum, dendrobium and other valuable Chinese herbs species selection, cultivation, processing and sales.
9, Taiji Group (proprietary Chinese medicine)
Current price: 18.86, total market capitalization: 10.5 billion, circulating market capitalization: 10.5 billion, three quarters of 2021: 0.45
Theme concept: one of the leading proprietary Chinese medicines, the pre-priority proprietary Chinese medicine plate leader, the performance of the big increase in the expected.
Main business: import and export business of proprietary Chinese medicines, western medicines, health care products, medical packaging products, medical equipment production and marketing and raw materials, Chinese herbal medicines, pharmaceutical packaging.
10, Jiang Zhong Pharmaceutical (pCms)
Current price: 11.81, total market capitalization: 7.440 billion, circulating market capitalization: 7.373 billion, 2021 three quarters: 0.72
Theme concepts: one of the leading pCms, the old OTC companies, Jiang Zhong brand stomach-healthy elimination tablets.
Main business: engaged in the production, research and development and sales of drugs and major health products.
11, Tongtse medical (medical services)
Current price: 11.81, total market capitalization: 47.6 billion, market capitalization in circulation: 47.6 billion, three quarters in 2021: 1.93
Theme concept: the leading stock of domestic oral health care.
Main business: investment management, the operation of medical equipment, import and export business, technology development, technology consulting, technology training and technical services, as well as other not need to be reported for approval of all legal projects
12, Weining Health (medical services)
The current price: 11.51, total market capitalization: 24.7 billion. Outstanding market capitalization: 20.8 billion, 2021 Q3: 0.12
Thematic concept: domestic medical information technology (cloud platform) leading stocks.
Main business: the company is mainly engaged in medical software research and development, sales and technical services business, and provide overall solutions for the health care industry information technology.
13, Star Lake technology (new crown special drugs concept)
Current price: 5.78, total market capitalization: 4.272 billion, the circulating market of 4.272 billion, the third quarter of 2021: 0.108
Theme concepts: Asset injection, the new crown special drugs, the performance of the big increase in the expected. Wholly-owned subsidiary Sichuan Jiuling Pharmaceutical is currently the largest domestic anti-HIVI virus drug ritonavir API manufacturer, ritonavir is Pfizer's new crown of oral special drugs important API.
Main business: production and sales of chemical APIs, nucleoside (acid) and amino acid biochemical products; edible flavorings, seasoning products, etc..
14, Taiyo Bio (new crown potent drug concept)
Current price: 34.58, total market capitalization: 2.075 billion, the circulating market capitalization: 1.407 billion, 2021 three quarters: 1.16
Issue Concept: Pfizer's new crown drug is an important raw material, ethyl trifluoroacetate producers, and pricing. Comparison of high.
Main business: engaged in inorganic salts, veterinary APIs and other chemical raw material products production and sales.
15, cutting-edge biology (new crown special drug concept)
Current price: 15.92, total market capitalization: 5.727 billion, the circulation of the market capitalization: 2.993 billion, the third quarter of 2021: -0.49
Theme concepts: the company's injectable anti-coronavirus in the research of the new drug FB2001, has been in the U.S. to carry out clinical phase 1 trials, and has been the first time in the United States. clinical phase 1 trial, and has been approved to carry out clinical phase 1 bridging trial in China.
Main Business: Dedicated to the research, development, manufacture and marketing of innovative medicines that address significant unmet clinical needs.
Not recommended or implied, investment risk, enter the market with caution.